# US 2026/0085357 A1 · Compositions, systems, and methods for detection of ovarian cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0085357 A1
- Document ID: US20260085357A1
- Status: Published application
- Kind: A1
- Application number: 19/114,203
- Filed: 2023-09-26
- Published: 2026-03-26
- Earliest claimed: 2022-09-26
- Inventors: Manson Fok; Kang Zhang
- Web page: https://patentgrep.com/patent/US20260085357A1

## CPC

- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- G16B 20/20: Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
- G16B 40/20: Supervised data analysis
- C12Q 2600/118: Prognosis of disease development
- C12Q 2600/154: Methylation markers
- C12Q 2600/156: Polymorphic or mutational markers
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- G16B: BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY

## Abstract

Compositions and methods for diagnosis and evaluation of prognosis of epithelial ovarian cancer (EOC) are provided. Development of an artificial intelligence approach entitled MethylBert and its application to identification of methylation sites useful in identification of EOC from cell free DNA obtained from serum or plasma is shown. PCR-based methods directed to the methylation state of the OV-1 site identified using MethylBERT approach can be used in screening for EOC using cell free DNA obtained from blood samples, and can be combined with measurement of tumor markers associated with EOC.

## Claims

### Claim 1

A method of assisting in diagnoses of endothelial ovarian cancer, comprising:
isolating cell-free genetic material from an individual; and
characterizing nucleic acid methylation of one or more genetic markers selected from the group consisting of OV1, OV2, OV6, OV3, OV4, OV5, OV6, OV6, OV6, OV6, OV7, OV8, OV9, OV10, OV11, OV12, OV13, OV14, OV15, OV16, OV17, OV18, OV19, OV20, OV21, and OV22,
wherein aberrant methylation of one or more genetic marker is indicative of endothelial ovarian cancer.

### Claim 2 (depends on 1)

The method of claim 1, wherein the cell-free genetic material is cell-free DNA.

### Claim 3 (depends on 1)

The method of claim 1, comprising treating at least a portion of the cell-free genetic material with bisulfite.

### Claim 4 (depends on 1)

The method of claim 1, comprising contacting the cell-free genetic material with a nucleic acid primer complementary to a portion of the genetic material proximal to at least one of the group consisting of OV1, OV2, OV6, OV3, OV4, OV5, OV6, OV6, OV6, OV6, OV7, OV8, OV9, OV10, OV11, OV12, OV13, OV14, OV15, OV16, OV17, OV18, OV19, OV20, OV21, and OV22_and performing an nucleic acid amplification to generate an amplification product.

### Claim 5 (depends on 4)

The method of claim 4, comprising contacting the amplification product with a probe that is complementary to at least of the group consisting of OV1, OV2, OV6, OV3, OV4, OV5, OV6, OV6, OV6, OV6, OV7, OV8, OV9, OV10, OV11, OV12, OV13, OV14, OV15, OV16, OV17, OV18, OV19, OV20, OV21, and OV22.

### Claim 6 (depends on 1)

The method of claim 1, comprising characterizing levels of CA125, wherein elevated levels of CA125 are indicative of endothelial ovarian cancer.

### Claim 7 (depends on 1)

The method of claim 1, wherein the genetic marker is OV1.

### Claim 8

A method of assisting in determining a prognosis for endothelial ovarian cancer, comprising:
isolating cell-free genetic material from an individual; and
characterizing nucleic acid methylation of one or more genetic markers selected from the group consisting of OV1, OV2, OV6, OV3, [[ ]]OV4, OV5, OV6, OV6, OV6, OV6, OV7, OV8, OV9, OV10, OV11, OV12, OV13, OV14, OV15, OV16, OV17, OV18, OV19, OV20, OV21, and OV22,
wherein aberrant methylation of one or more genetic marker is indicative of a poor prognosis for endothelial ovarian cancer.

### Claim 9 (depends on 8)

The method of claim 8, wherein the cell-free genetic material is cell-free DNA.

### Claim 10 (depends on 8)

The method of claim 8, comprising treating at least a portion of the cell-free genetic material with bisulfite.

### Claim 11 (depends on 9)

The method of claim 9, comprising contacting the cell-free genetic material with a nucleic acid primer complementary to a portion of the genetic material proximal to at least one of the group consisting of OV1, OV2, OV6, OV3, OV4, OV5, OV6, OV6, OV6, OV6, OV7, OV8, OV9, OV10, OV11, OV12, OV13, OV14, OV15, OV16, OV17, OV18, OV19, OV20, OV21, and OV22_and performing an nucleic acid amplification to generate an amplification product.

### Claim 12 (depends on 11)

The method of claim 11, comprising contacting the amplification product with a probe that is complementary to at least of the group consisting of OV1, OV2, OV6, OV7, OV9, OV11, OV18, and OV22.

### Claim 13 (depends on 8)

The method of claim 8, comprising characterizing levels of CA125, wherein elevated levels of CA125 are indicative of a poor prognosis for endothelial ovarian cancer.

### Claim 14 (depends on 8)

The method of claim 8, wherein the genetic marker is OV1.

### Claim 15 (depends on 1)

The method of claim 1, further comprising, prior to the step of characterizing methylation, applying an artificial intelligence algorithm to a training dataset comprising individuals identified as having EOC and individuals without EOC and identifying a methylation pattern associated with individuals with EOC, wherein the artificial intelligence algorithm comprises correlation with chromosome embedding, position embedding, methylation level embedding, and gene embedding, and wherein the methylation pattern comprises one or more genetic markers exhibiting methylation differences between individuals with EOC and individuals without EOC.

### Claim 16 (depends on 15)

The method of claim 15, wherein the artificial intelligence algorithm comprises a matrix decomposition-based Transformer model configured to reduce computational complexity from quadratic to linear (O(L2) to O(L)), thereby enabling efficient processing of large-scale data.

### Claim 17 (depends on 16)

The method of claim 16, wherein the Transformer model comprises a Performer, wherein the Performer comprises an attention mechanism formulated as Att(Q, K, V)=softmax(ΦQ)Φ(K)T/sqrt(dk)V, wherein Q, K, and V denote query, key, and value matrices, respectively and Φ signifies a feature map function that projects input into a new space, thereby improving efficient approximation of the dot-product attention.

### Claim 18

A composition for diagnosis or prognosis of endothelial ovarian cancer, comprising:
a first primer that is complementary to a first portion of nucleic acid proximal to at least one genetic marker selected from the group consisting of OV1, OV2, OV6, OV3, OV4, OV5, OV6, OV6, OV6, OV6, OV7, OV8, OV9, OV10, OV11, OV12, OV13, OV14, OV15, OV16, OV17, OV18, OV19, OV20, OV21, and OV22; and
a probe that is complementary to at least one genetic marker selected from the group consisting of OV1, OV2, OV6, OV3, OV4, OV5, OV6, OV6, OV6, OV6, OV7, OV8, OV9, OV10, OV11, OV12, OV13, OV14, OV15, OV16, OV17, OV18, OV19, OV20, OV21, and OV22 and that comprises a first dye or a first fluorophore.

### Claim 19 (depends on 18)

The composition of claim 18, further comprising a second primer that is complementary to a genetic marker selected from the group consisting of OV1, OV2, OV6, OV3, OV4, OV5, OV6, OV6, OV6, OV6, OV7, OV8, OV9, OV10, OV11, OV12, OV13, OV14, OV15, OV16, OV17, OV18, OV19, OV20, OV21, and OV22.

### Claim 20 (depends on 19)

The composition of claim 19, comprising a second probe that is complementary to a genetic marker selected from the group consisting of OV1, OV2, OV6, OV3, OV4, OV5, OV6, OV6, OV6, OV6, OV7, OV8, OV9, OV10, OV11, OV12, OV13, OV14, OV15, OV16, OV17, OV18, OV19, OV20, OV21, and OV22, optionally, wherein the second probe comprises a second dye or a second fluorophore.

### Claim 21

(canceled)
